# Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast Cancer

> **NCT00617942** · PHASE2 · COMPLETED · sponsor: **William Sikov MD** · enrollment: 60 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Cohort 1 neo-adjuvant
- **DRUG:** Cohort 2 neo-adjuvant
- **DRUG:** Cohort 1 adjuvant
- **DRUG:** Cohort 2 adjuvant

## Key facts

- **NCT ID:** NCT00617942
- **Lead sponsor:** William Sikov MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2012-08
- **Final completion:** 2015-12
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2020-06-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00617942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00617942, "Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00617942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*